Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.
about
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusionVEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and ratsCCR3 is a target for age-related macular degeneration diagnosis and therapyIdiopathic juxtafoveolar retinal telangiectasis: a current reviewNRP1 function and targeting in neurovascular development and eye diseaseAngiogenic factors, bladder neuroplasticity and interstitial cystitis-new pathobiological insightsGeographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospectsNerve Growth Factor: A Focus on Neuroscience and TherapyFunctions of Müller cell-derived vascular endothelial growth factor in diabetic retinopathyBrain homeostasis: VEGF receptor 1 and 2-two unequal brothers in mindMechanisms of age-related macular degenerationTherapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathyA review of anti-VEGF agents for proliferative diabetic retinopathyAAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularizationStructure-function correlation of the human central retinaAnti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical applicationAxl is essential for VEGF-A-dependent activation of PI3K/AktArhgef15 promotes retinal angiogenesis by mediating VEGF-induced Cdc42 activation and potentiating RhoJ inactivation in endothelial cellsVascular endothelial growth factor protects post-ganglionic sympathetic neurones from the detrimental effects of hydrogen peroxide by increasing catalaseExacerbation of retinal degeneration in the absence of alpha crystallins in an in vivo model of chemically induced hypoxiaThe related transcriptional enhancer factor-1 isoform, TEAD4(216), can repress vascular endothelial growth factor expression in mammalian cellsAptamers and the RNA world, past and presentFit for the Eye: Aptamers in Ocular DisordersPegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.Differential gene expression in the developing lateral geniculate nucleus and medial geniculate nucleus reveals novel roles for Zic4 and Foxp2 in visual and auditory pathway developmentTargeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration.Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cellsUse of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy.The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.Analysis of the retinal gene expression profile after hypoxic preconditioning identifies candidate genes for neuroprotection.Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptorsSystemic protection through remote ischemic preconditioning is spread by platelet-dependent signaling in mice.Current and emerging therapies for the treatment of age-related macular degenerationProlonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels.Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema.Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye.HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy.Development of choroidal neovascularization in rats with advanced intense cyclic light-induced retinal degenerationThe multifactorial nature of retinal vascular diseaseA safety study of high concentration and high frequency intravitreal injection of conbercept in rabbits
P2860
Q24194783-7292929E-6E54-4192-962B-CC87071A3EF1Q24312100-202CEE3A-6166-4BFE-8F13-F0B04C6BBCBBQ24338258-B67A8F9E-58FF-49D5-915D-16B4896F1947Q24616761-9B9BE30D-E0B1-4A2C-A8F2-7D6CC26C9DABQ26765952-E2BB1E99-F0F8-46A2-8A9B-F4050F5412ADQ26773577-4D7B54F9-5A12-47B6-B854-05F348E3CEB5Q26774188-609049D5-58A3-482A-AD5C-8884827EB1C8Q26786398-2E4D38CE-2229-48DE-A183-3E6E7F6BB0DAQ26824541-2E8E1B2F-0240-4457-8EEB-7F97978454F3Q26826870-B1D5791F-B1B3-460F-A83A-6AC6713C390EQ27000182-36959182-0F1A-491A-BB55-4C48258430C7Q27021701-2FCEDB3A-C0BC-4B73-BF7E-233FE6F6DE27Q27025643-49E89F91-C765-4AE6-9C5F-48B6175A82EEQ27318539-88AD5DCC-E516-44BB-9D4A-2693D803CBE6Q27319838-2B17DDE3-9227-4348-828A-4D028497EC53Q28082140-D1E15B70-B39B-43A9-B58C-6F9D8873CA08Q28116976-E1E2BA7A-16F5-4C85-AF6F-871F91F4B521Q28483947-1602AACC-1EC5-4EEC-AE65-63B2A884A80FQ28572195-EDD28EAB-37A6-4753-B6DC-BB235BD80827Q28585065-94350729-1D8F-40FE-ACAF-ECAB44E5E62CQ28728051-EA481406-2C81-45B3-A269-392CEA38541CQ28731938-C2887227-3AC6-4FA7-ACF1-F018B942A548Q28828283-9E3A02AC-B297-4BD8-ABCA-D3853D1EE375Q30440705-60915FF8-2B40-4199-9B6D-F264AACFAF66Q30465755-F0F62A2A-D91E-4CEE-A88D-BF233D5C5492Q30539153-81487D4F-3DB2-4101-80C9-F6066A96E944Q30579734-88CD4A4F-0AE7-4D2F-AD8A-C7FFD73D7029Q30979491-C719D61C-52A9-4C57-AE16-10C701AD284CQ31061150-5DA0DEF8-6F9E-4401-B15B-E8B3EF6337B4Q33318975-52BCF68A-1E30-46B9-869E-8A1458DEF604Q33382103-24A74378-0E10-425A-A9AA-12610BDF8343Q33414408-528AE192-D451-49A4-AC30-4EE40D36F161Q33492370-00242DF1-D2B2-4130-BAF2-7D97FFA47808Q33584304-8492EC26-C429-44F5-972B-955C7328B794Q33593437-A18089B9-7591-4069-ADF0-ACF909EFD44AQ33623357-C43A9D46-3F50-4037-A243-356F10FFEADFQ33641974-1925CBED-3922-430D-8D78-6F19185CE04DQ33645725-DCFF3B8F-3DF1-41C9-ABD7-93A6598020DFQ33660130-BF813283-6056-4BF7-98D8-6B0822B0D40BQ33674476-0A3D39CD-C350-4785-B41B-35872AA33D6C
P2860
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Vascular endothelial growth fa ...... ve response to ischemic injury
@nl
Vascular endothelial growth fa ...... e response to ischemic injury.
@ast
Vascular endothelial growth fa ...... e response to ischemic injury.
@en
type
label
Vascular endothelial growth fa ...... ve response to ischemic injury
@nl
Vascular endothelial growth fa ...... e response to ischemic injury.
@ast
Vascular endothelial growth fa ...... e response to ischemic injury.
@en
prefLabel
Vascular endothelial growth fa ...... ve response to ischemic injury
@nl
Vascular endothelial growth fa ...... e response to ischemic injury.
@ast
Vascular endothelial growth fa ...... e response to ischemic injury.
@en
P2093
P2860
P3181
P1476
Vascular endothelial growth fa ...... ve response to ischemic injury
@en
P2093
Anthony P Adamis
David T Shima
Gregory S Robinson
John Bradley
Kazuaki Nishijima
Lichun Zhong
Steven J Samuelsson
William Schubert
P2860
P3181
P356
10.2353/AJPATH.2007.061237
P407
P577
2007-07-01T00:00:00Z